3Dnamics initial aim has been to engineer 3D organoid models of biological systems and diseases using human to accelerate the discovery and development of novel therapeutics and medicines for intractable neurological diseases.
The quest to find novel therapeutics for neurological disorders has been hindered by the lack of access to relevant samples and experimental models. Currently, roughly 0.1% of drugs that show promise in preclinical testing make it to Phase 1 clinical trials.
Their platform has been successfully applied to model Zika virus-induced microcephaly, toxicity testing, and validation of novel therapeutic compounds for Zika virus infection.
In collaboration with National Institute of Health they are working towards discovering novel compounds for rare neurological diseases, such as ALS and Frontotemporal Dementia.
3Dnamics Inc. was founded in 2016 by leading-edge stem cell pioneers and neuroscientists at Johns Hopkins University.
CEO and President: Ha Nam Nguyen
3Dnamics has developed a platform consisting of a multi-well bioreactor and a set of methods to generate brain-region-specific organoids in 3D culture. The bioreactor allows organoids to grow in suspension, enhances organoids oxygen and nutrient uptakes to improve survival, and to maintain their shape and architecture.